MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- IPCA LABS - AUROBINDO PHARMA
IPCA LABS vs AUROBINDO PHARMA - Comparison Results
IPCA LABS 
Change
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
AUROBINDO PHARMA
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Current Valuations
| IPCA LABS | AUROBINDO PHARMA | IPCA LABS/ AUROBINDO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 30.8 | 21.0 | 146.6% | View Chart |
| P/BV | x | 4.5 | 4.1 | 109.6% | View Chart |
| Dividend Yield | % | 0.1 | 0.3 | 34.2% |
Financials
 IPCA LABS  AUROBINDO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| IPCA LABS Mar-18 |
AUROBINDO PHARMA Mar-18 |
IPCA LABS/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 695 | 809 | 86.0% | |
| Low | Rs | 400 | 504 | 79.4% | |
| Sales per share (Unadj.) | Rs | 260.2 | 281.1 | 92.6% | |
| Earnings per share (Unadj.) | Rs | 19.0 | 41.4 | 45.9% | |
| Cash flow per share (Unadj.) | Rs | 33.1 | 50.9 | 65.0% | |
| Dividends per share (Unadj.) | Rs | 1.00 | 2.50 | 40.0% | |
| Dividend yield (eoy) | % | 0.2 | 0.4 | 47.9% | |
| Book value per share (Unadj.) | Rs | 213.0 | 199.4 | 106.9% | |
| Shares outstanding (eoy) | m | 126.20 | 585.88 | 21.5% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.1 | 2.3 | 90.1% | |
| Avg P/E ratio | x | 28.9 | 15.9 | 181.9% | |
| P/CF ratio (eoy) | x | 16.6 | 12.9 | 128.4% | |
| Price / Book Value ratio | x | 2.6 | 3.3 | 78.1% | |
| Dividend payout | % | 5.3 | 6.0 | 87.2% | |
| Avg Mkt Cap | Rs m | 69,120 | 384,630 | 18.0% | |
| No. of employees | `000 | 13.3 | 17.3 | 76.5% | |
| Total wages/salary | Rs m | 7,359 | 21,308 | 34.5% | |
| Avg. sales/employee | Rs Th | 2,477.4 | 9,500.7 | 26.1% | |
| Avg. wages/employee | Rs Th | 555.2 | 1,229.4 | 45.2% | |
| Avg. net profit/employee | Rs Th | 180.6 | 1,397.9 | 12.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 32,836 | 164,666 | 19.9% | |
| Other income | Rs m | 418 | 1,020 | 41.0% | |
| Total revenues | Rs m | 33,254 | 165,686 | 20.1% | |
| Gross profit | Rs m | 4,505 | 37,718 | 11.9% | |
| Depreciation | Rs m | 1,777 | 5,580 | 31.9% | |
| Interest | Rs m | 240 | 777 | 30.9% | |
| Profit before tax | Rs m | 2,905 | 32,380 | 9.0% | |
| Minority Interest | Rs m | 0 | 31 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 511 | 8,183 | 6.2% | |
| Profit after tax | Rs m | 2,394 | 24,229 | 9.9% | |
| Gross profit margin | % | 13.7 | 22.9 | 59.9% | |
| Effective tax rate | % | 17.6 | 25.3 | 69.6% | |
| Net profit margin | % | 7.3 | 14.7 | 49.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 19,455 | 121,878 | 16.0% | |
| Current liabilities | Rs m | 10,076 | 86,806 | 11.6% | |
| Net working cap to sales | % | 28.6 | 21.3 | 134.1% | |
| Current ratio | x | 1.9 | 1.4 | 137.5% | |
| Inventory Days | Days | 98 | 130 | 75.4% | |
| Debtors Days | Days | 67 | 68 | 97.9% | |
| Net fixed assets | Rs m | 20,260 | 81,037 | 25.0% | |
| Share capital | Rs m | 252 | 586 | 43.1% | |
| "Free" reserves | Rs m | 26,633 | 116,218 | 22.9% | |
| Net worth | Rs m | 26,886 | 116,804 | 23.0% | |
| Long term debt | Rs m | 2,340 | 4,512 | 51.9% | |
| Total assets | Rs m | 41,173 | 211,052 | 19.5% | |
| Interest coverage | x | 13.1 | 42.7 | 30.7% | |
| Debt to equity ratio | x | 0.1 | 0 | 225.3% | |
| Sales to assets ratio | x | 0.8 | 0.8 | 102.2% | |
| Return on assets | % | 6.4 | 11.8 | 54.0% | |
| Return on equity | % | 8.9 | 20.7 | 42.9% | |
| Return on capital | % | 10.8 | 27.4 | 39.3% | |
| Exports to sales | % | 47.6 | 0 | - | |
| Imports to sales | % | 14.9 | 0 | - | |
| Exports (fob) | Rs m | 15,642 | NA | - | |
| Imports (cif) | Rs m | 4,884 | NA | - | |
| Fx inflow | Rs m | 15,642 | 80,727 | 19.4% | |
| Fx outflow | Rs m | 4,884 | 34,700 | 14.1% | |
| Net fx | Rs m | 10,759 | 46,027 | 23.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,411 | 19,548 | 17.5% | |
| From Investments | Rs m | -1,354 | -19,570 | 6.9% | |
| From Financial Activity | Rs m | -1,304 | 8,642 | -15.1% | |
| Net Cashflow | Rs m | 753 | 8,922 | 8.4% | |
Share Holding
| Indian Promoters | % | 45.9 | 54.1 | 84.8% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 11.4 | 8.0 | 143.4% | |
| FIIs | % | 25.3 | 27.7 | 91.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.4 | 10.2 | 170.6% | |
| Shareholders | 36,892 | 69,601 | 53.0% | ||
| Pledged promoter(s) holding | % | 2.1 | 8.6 | 25.0% |
Compare IPCA LABS With: FDC LTD. UNICHEM LAB WYETH LTD JUBILANT LIFE SCIENCES STRIDES PHARMA SCIENCE
Compare IPCA LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Trades Higher; Metal Stocks Lead(12:30 pm)
Stock markets in India are presently witnessing buying interest. The BSE Sensex is trading up by 95 points and the NSE Nifty is trading up by 38 points.
Related Views on News
IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 19, 2018 | Updated on Dec 19, 2018Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)
Nov 15, 2018 | Updated on Nov 15, 2018For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsMost Popular
My Master Series on How to Trade Election 2019(Profit Hunter)
Apr 16, 2019For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...
Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)
Apr 17, 201920% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.
The Best Trading Strategy in the World(Profit Hunter)
Apr 15, 2019It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...
A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)
Apr 15, 2019It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...
Election Series: Why 'Liquor' is so Important to the Elections(The 5 Minute Wrapup)
Apr 19, 2019When elections come around, liquor flows like water and everyone gets drunk with power...what does this mean for liquor stocks? Read one to find out from our very own election trading analyst, Vijay Bhambwani.
More|
| |
IPCA LABS SHARE PRICE
Apr 26, 2019 03:05 PM
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS - PIRAMAL ENTERPRISES COMPARISON
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.